JP2018513149A5 - - Google Patents

Download PDF

Info

Publication number
JP2018513149A5
JP2018513149A5 JP2017552973A JP2017552973A JP2018513149A5 JP 2018513149 A5 JP2018513149 A5 JP 2018513149A5 JP 2017552973 A JP2017552973 A JP 2017552973A JP 2017552973 A JP2017552973 A JP 2017552973A JP 2018513149 A5 JP2018513149 A5 JP 2018513149A5
Authority
JP
Japan
Prior art keywords
seq
variable domain
chain variable
amino acid
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017552973A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018513149A (ja
JP7068825B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/026567 external-priority patent/WO2016164669A2/en
Publication of JP2018513149A publication Critical patent/JP2018513149A/ja
Publication of JP2018513149A5 publication Critical patent/JP2018513149A5/ja
Priority to JP2021086783A priority Critical patent/JP7273101B2/ja
Application granted granted Critical
Publication of JP7068825B2 publication Critical patent/JP7068825B2/ja
Priority to JP2022101169A priority patent/JP2022118222A/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017552973A 2015-04-08 2016-04-08 Ｃｄ３８に結合する抗体治療剤 Expired - Fee Related JP7068825B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021086783A JP7273101B2 (ja) 2015-04-08 2021-05-24 Ｃｄ３８に結合する抗体治療剤
JP2022101169A JP2022118222A (ja) 2015-04-08 2022-06-23 Ｃｄ３８に結合する抗体治療剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562144901P 2015-04-08 2015-04-08
US62/144,901 2015-04-08
PCT/US2016/026567 WO2016164669A2 (en) 2015-04-08 2016-04-08 Antibody therapeutics that bind cd38

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021086783A Division JP7273101B2 (ja) 2015-04-08 2021-05-24 Ｃｄ３８に結合する抗体治療剤

Publications (3)

Publication Number Publication Date
JP2018513149A JP2018513149A (ja) 2018-05-24
JP2018513149A5 true JP2018513149A5 (2) 2019-05-16
JP7068825B2 JP7068825B2 (ja) 2022-05-17

Family

ID=57072959

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017552973A Expired - Fee Related JP7068825B2 (ja) 2015-04-08 2016-04-08 Ｃｄ３８に結合する抗体治療剤
JP2021086783A Active JP7273101B2 (ja) 2015-04-08 2021-05-24 Ｃｄ３８に結合する抗体治療剤
JP2022101169A Pending JP2022118222A (ja) 2015-04-08 2022-06-23 Ｃｄ３８に結合する抗体治療剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021086783A Active JP7273101B2 (ja) 2015-04-08 2021-05-24 Ｃｄ３８に結合する抗体治療剤
JP2022101169A Pending JP2022118222A (ja) 2015-04-08 2022-06-23 Ｃｄ３８に結合する抗体治療剤

Country Status (8)

Country Link
US (4) US9951144B2 (2)
EP (2) EP4180058A1 (2)
JP (3) JP7068825B2 (2)
CN (2) CN107921122B (2)
AR (1) AR104213A1 (2)
ES (1) ES2927119T3 (2)
TW (1) TW201702264A (2)
WO (2) WO2016164669A2 (2)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10100118B2 (en) * 2015-04-08 2018-10-16 Sorrento Therapeutics, Inc. Antibody therapeutics that bind CD123
US9951144B2 (en) 2015-04-08 2018-04-24 Sorrento Therapeutics, Inc. Antibody therapeutics that bind CD38
US10676516B2 (en) 2017-05-24 2020-06-09 Pandion Therapeutics, Inc. Targeted immunotolerance
MY201312A (en) 2017-06-02 2024-02-16 Pfizer Antibodies specific for flt3 and their uses
CN110997722B (zh) 2017-06-08 2023-09-26 黑带医疗有限公司 Cd38调节抗体
JP7679196B2 (ja) 2017-06-08 2025-05-19 ブラック ベルト セラピューティクス リミテッド Ｃｄ３８調節抗体
EP3641831B1 (en) * 2017-06-20 2024-11-06 Sorrento Therapeutics, Inc. Cd38 antibody drug conjugate
US11542338B2 (en) 2017-08-16 2023-01-03 Black Belt Therapeutics Limited CD38 modulating antibody
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
CA3073085A1 (en) 2017-08-16 2019-02-21 Black Belt Therapeutics Limited Cd38 modulating antibody
KR102770110B1 (ko) * 2017-08-16 2025-02-20 블랙 벨트 테라퓨틱스 리미티드 Cd38 항체
CA3080109A1 (en) * 2017-11-03 2019-05-09 Sorrento Therapeutics, Inc. Cd38-directed chimeric antigen receptor constructs
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
AU2019231315A1 (en) * 2018-03-09 2020-09-17 Vivasor, Inc. Dimeric antigen receptors (DAR)
CA3103114A1 (en) 2018-06-20 2019-12-26 Sorrento Therapeutics, Inc. Variant antibody that binds cd38
AU2019338999A1 (en) * 2018-09-11 2021-03-18 Jiangsu Hengrui Medicine Co., Ltd. Anti-CD38 antibody, antigen-binding fragment thereof, and pharmaceutical use
CA3134612A1 (en) * 2019-03-29 2020-10-08 Sorrento Therapeutics, Inc. Engineered variant antibodies that bind cd38
BR112021023345A2 (pt) 2019-05-20 2022-02-01 Pandion Operations Inc Imunotolerância com alvo em madcam
AU2020299774A1 (en) * 2019-07-03 2022-01-20 Peptidream Inc. CD38-binding agents and uses thereof
BR112022003163A2 (pt) * 2019-08-19 2022-05-17 Pandion Operations Inc Imunotolerância alvejada com um agonista de pd-1
US20210221886A1 (en) 2019-12-05 2021-07-22 Sorrento Therapeutics, Inc. Compositions and Methods Comprising an Anti-CD47 Antibody in Combination with a Tumor Targeting Antibody
EP4107187A4 (en) 2020-02-21 2024-07-03 Pandion Operations, Inc. TISSUE-TARGETED IMMUNOTOLERANCE WITH A CD39 EFFECTOR
EP4107189A4 (en) * 2020-02-21 2024-07-03 Pandion Operations, Inc. TISSUE-TARGETED IMMUNOTOLERANCE WITH PD-1 AGONISTS OR IL-2 MUTEINS
WO2022015956A1 (en) 2020-07-15 2022-01-20 Sorrento Therapeutics, Inc. Improved process for dna integration using rna-guided endonucleases
CA3188732A1 (en) * 2020-08-19 2022-02-24 Nathan HIGGINSON-SCOTT Multi-paratopic anti-pd-1 antibodies and uses thereof
KR20230066404A (ko) * 2020-09-10 2023-05-15 카시 파마슈티컬스, 인코포레이티드 혈액 스크리닝 방법

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3817827A (en) 1972-03-30 1974-06-18 Scott Paper Co Soft absorbent fibrous webs containing elastomeric bonding material and formed by creping and embossing
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US6010902A (en) 1988-04-04 2000-01-04 Bristol-Meyers Squibb Company Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
JP3051145B2 (ja) 1990-08-28 2000-06-12 住友製薬株式会社 新規なポリエチレングリコール誘導体修飾ペプチド
US5582996A (en) 1990-12-04 1996-12-10 The Wistar Institute Of Anatomy & Biology Bifunctional antibodies and method of preparing same
DE4118120A1 (de) 1991-06-03 1992-12-10 Behringwerke Ag Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
PT672141E (pt) 1992-10-23 2003-09-30 Immunex Corp Metodos de preparacao de proteinas oligomericas soluveis
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
EP1105427A2 (en) 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
GB9928787D0 (en) 1999-12-03 2000-02-02 Medical Res Council Direct screening method
PT2281843T (pt) 2000-06-16 2017-01-02 Human Genome Sciences Inc Anticorpos que se ligam imunoespecificamente a blys
US6938003B2 (en) 2000-06-30 2005-08-30 Mahesh Harpale Method and apparatus for a credibility reporting system to augment an online exchange
GB0025144D0 (en) 2000-10-13 2000-11-29 Medical Res Council Concatenated nucleic acid sequences
CA2450793A1 (en) * 2001-06-20 2002-12-27 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
US20040202995A1 (en) 2003-04-09 2004-10-14 Domantis Nucleic acids, proteins, and screening methods
KR20140066259A (ko) 2004-02-06 2014-05-30 모르포시스 아게 항-ｃｄ３８ 인간 항체 및 그의 용도
CN1976950B (zh) * 2004-02-06 2012-08-29 莫佛塞斯公司 抗cd38人抗体及其用途
JP5225069B2 (ja) * 2005-03-23 2013-07-03 ゲンマブ エー／エス 多発性骨髄腫の治療のためのｃｄ３８に対する抗体
CA2625681C (en) * 2005-10-12 2016-08-02 Morphosys Ag Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38
CA2742969A1 (en) 2008-11-07 2010-05-14 Fabrus Llc Anti-dll4 antibodies and uses thereof
WO2010141249A2 (en) 2009-06-02 2010-12-09 Merck Sharp & Dohme Corp. Generation, characterization and uses thereof of anti-notch3 antibodies
SMT202000031T1 (it) 2010-06-09 2020-03-13 Genmab As Anticorpi contro cd38 umano
DK2621531T3 (en) * 2010-09-27 2017-02-27 Morphosys Ag ANTI-CD38 ANTIBODY AND LENALIDOMIDE OR BORTEZOMIB FOR TREATMENT OF MULTIPLE MYELOM AND NHL
JOP20210044A1 (ar) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
US9120858B2 (en) * 2011-07-22 2015-09-01 The Research Foundation Of State University Of New York Antibodies to the B12-transcobalamin receptor
EP3021866A4 (en) * 2013-07-15 2017-02-22 The Board of Trustees of the Leland Stanford Junior University Medical uses of cd38 agonists
US9951144B2 (en) 2015-04-08 2018-04-24 Sorrento Therapeutics, Inc. Antibody therapeutics that bind CD38

Similar Documents

Publication Publication Date Title
JP2018513149A5 (2)
JP2017501157A5 (2)
JP2018519263A5 (2)
JP2021531005A5 (2)
JP2021533726A5 (2)
JP2018500014A5 (2)
CL2013003373A1 (es) Proteina de union al antigeno de maduración de linfocitos b (bcma); composicion farmacéutica que comprende la proteína; uso para preparar un medicamento util para tratar mieloma multiple o (mm) leucemia linfocitica cronica (cll).
JP2020504723A5 (2)
JP2017536829A5 (2)
RU2016128726A (ru) Способы лечения злокачественных опухолей с использованием антагонистов связывания по оси pd-1 и антитела против cd20
JP2023543152A5 (2)
JP2015163068A5 (2)
JP2017502667A5 (2)
RU2016137110A (ru) Антитела к компоненту комплемента с5
JP2019507183A5 (2)
JP2015525795A5 (2)
JP2015511817A5 (2)
JP2017528462A5 (2)
JP2016503067A5 (2)
JP2012526558A5 (2)
JP2017500057A5 (2)
RU2018126297A (ru) Антитела, нацеленные на cd32b, и способы их применения
JP2016512223A5 (2)
JP2020516309A5 (2)
JP2020502147A5 (2)